ENvue Medical Inc. (FEED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ENvue Medical Inc. (FEED) has a cash flow conversion efficiency ratio of -0.087x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.69 Million) by net assets ($30.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is ENvue Medical Inc. worth for the company's overall valuation and market capitalisation.
ENvue Medical Inc. - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how ENvue Medical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View ENvue Medical Inc. (FEED) share price today for real-time trading data and today's change.
ENvue Medical Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENvue Medical Inc. ranked by their cash flow conversion efficiency. Review FEED financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LIVE MOTION GAMES ZY -10
F:4YM
|
0.873x |
|
ALBERT LABS INTL. CORP.
F:VB50
|
N/A |
|
PROPHECY DEFI INC.
F:V8M
|
N/A |
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
-0.522x |
|
Alkemy Capital Investments Plc
LSE:ALK
|
1.013x |
|
Metgasco Ltd
AU:MEL
|
0.075x |
|
Nevada Zinc Corp
V:NZN
|
0.109x |
|
Sparx Technology Inc
V:SPRX
|
0.114x |
Annual Cash Flow Conversion Efficiency for ENvue Medical Inc. (2011–2025)
The table below shows the annual cash flow conversion efficiency of ENvue Medical Inc. from 2011 to 2025. Also see ENvue Medical Inc. balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $33.50 Million | $-9.37 Million | -0.280x | +93.03% |
| 2024-12-31 | $627.00K | $-2.52 Million | -4.013x | -344.28% |
| 2023-12-31 | $3.99 Million | $-3.60 Million | -0.903x | +58.49% |
| 2022-12-31 | $3.23 Million | $-7.04 Million | -2.176x | -214.57% |
| 2021-12-31 | $6.31 Million | $-4.37 Million | -0.692x | +51.16% |
| 2020-12-31 | $2.39 Million | $-3.39 Million | -1.416x | +50.71% |
| 2019-12-31 | $1.35 Million | $-3.87 Million | -2.874x | +62.52% |
| 2018-12-31 | $463.00K | $-3.55 Million | -7.667x | -1176.96% |
| 2017-12-31 | $3.63 Million | $-2.18 Million | -0.600x | -197.88% |
| 2016-12-31 | $-2.50 Million | $-1.53 Million | 0.613x | -91.34% |
| 2015-12-31 | $-209.00K | $-1.48 Million | 7.081x | +4318.76% |
| 2014-12-31 | $-5.62 Million | $-900.00K | 0.160x | -12.23% |
| 2013-12-31 | $-3.30 Million | $-602.00K | 0.183x | -57.50% |
| 2012-12-31 | $-1.83 Million | $-787.00K | 0.430x | -54.06% |
| 2011-12-31 | $-585.00K | $-547.00K | 0.935x | -- |
About ENvue Medical Inc.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, incre… Read more